Reach Us +1-218-451-2974


Carbamylated Erythropoietin-FC Protects Hippocampus Against A Induced Memory Deterioration In A Rat Model Of A Toxicity: Considering Akt/GSK-3, MAPKs And MMP-2 | 99438
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 2275

Journal of Alzheimers Disease & Parkinsonism received 2275 citations as per Google Scholar report

Journal of Alzheimers Disease & Parkinsonism peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Carbamylated erythropoietin-FC protects hippocampus against A induced memory deterioration in a rat model of A toxicity: Considering Akt/GSK-3, MAPKs and MMP-2

12th International Conference on Alzheimer's Disease & Dementia

Etrat Hooshmandi, Fereshteh Motamedi, Maryam Moosavi, Rasoul Ghasemi and Nader Maghsoudi

Shahid Beheshti University of Medical Sciences, IranShiraz University of Medical Sciences, Iran

ScientificTracks Abstracts: J Alzheimers Dis Parkinsonism

DOI: 10.4172/2161-0460-C7-054

Alzheimer's disease (AD) is a debilitating neurodegenerative disease, characterized by extracellular deposition of senile plaques, mostly amyloid ?-protein (A?) and neuronal loss. It has been reported that erythropoietin (EPO) has neuroprotective effects in some models of neurodegenerative disease but because of its hematopoietic side effects, its derivatives lacking hematopoietic bioactivity is recommended. This study evaluated the neuroprotective effects of carbamylated erythropoietin-FC (CEPO-FC) against beta amyloid induced memory deficit. Adult male Wistar rats weighing 250???300 g were cannulated bilaterally into CA1. A?25???35 was administered intra hippocampally for four consecutive days (5 ?g/2.5 ?L/each side/day). CEPO-FC (500 or 5000 IU) was injected intraperitoneally during the days 4???9. Learning and memory performance of rats was assessed on days 10???13 using Morris water maze and then the hippocampi were isolated and the amount of activated forms of hippocampal MAPKs subfamily, Akt/GSK-3? and MMP-2 were analyzed by western blot. The behavioral results revealed that CEPO-FC treatment in both 500 and 5000 IU significantly reversed A?-induced learning and memory deterioration. Molecular analysis showed an increment of MAPKs and MMP-2 activity and an imbalance in Akt/GSK- 3? signaling after A?25???35 administration. CEPO-FC treatment prevented the elevation hippocampal of P38, ERK, MMP-2 activity and also Akt/GSK-3? signaling impairment induced by A?25???35; however, it had no effect on c-Jun N-terminal kinase (JNK). It seems that CEPO-FC prevents A?-induced learning and memory deterioration and modulates hippocampal MAPKs, Akt/GSK-3? and MMP-2 activity. This study suggests CEPO-FC can be considered as a potential therapeutic strategy for memory deficits like AD.

Etrat Hooshmandi is a PhD student of Neuroscience at Shahid Beheshti University of Medical Sciences, Tehran, Iran. Her thesis and projects are about therapeutic targets and molecular signaling in rat models of Alzheimer's diseases.

E-mail: [email protected]